Trial · NCT01146288
Effect of Acetazolamide and Furosemide on Obesity-induced Glomerular Hyperfiltration
NCT01146288, Not applicable, Completed, Rabin Medical Center; results first posted 2015-06-04
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Acetazolamide and Furosemide on Obesity-induced Glomerular Hyperfiltration. Trials, record NCT01146288. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01146288
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Acetazolamide and Furosemide on Obesity-induced Glomerular Hyperfiltration
- NCT number
- NCT01146288
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 13 participants, actual
- Lead sponsor
- Rabin Medical Center
- Conditions
- Obesity-induced Hyperfiltration
- Interventions
- Furosemide first, then Acetazolamide, Acetazolamide first, then Furosemide
- First posted
- 2010-06-17
- Last updated
- 2015-06-04
- Results first posted
- 2015-06-04
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in GFR (ml/Min) | baseline and after diuretics administration | |
| Primary | Renal Vascular Resistance (mm Hg/[ml/Min]) | baseline and after diuretics administration |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in GFR (ml/Min) | baseline and after diuretics administration | ml/min | MEAN | |
| PRIMARY | Renal Vascular Resistance (mm Hg/[ml/Min]) | baseline and after diuretics administration | mm Hg/[ml/min] | MEAN |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in GFR (ml/Min) | Acetazolamide | GFR before acetazolamide/furosemide administration | 151 | Standard Deviation 22 | ml/min |
| Change in GFR (ml/Min) | Furosemide | GFR before acetazolamide/furosemide administration | 152 | Standard Deviation 18 | ml/min |
| Change in GFR (ml/Min) | Acetazolamide | GFR after acetazolamide/furosemide administration | 120 | Standard Deviation 16 | ml/min |
| Change in GFR (ml/Min) | Furosemide | GFR after acetazolamide/furosemide administration | 150 | Standard Deviation 28 | ml/min |
| Renal Vascular Resistance (mm Hg/[ml/Min]) | Acetazolamide | before acetazolamide/furosemide administration | 0.078 | Standard Deviation 1.017 | mm Hg/[ml/min] |
| Renal Vascular Resistance (mm Hg/[ml/Min]) | Furosemide | before acetazolamide/furosemide administration | 0.073 | Standard Deviation 0.010 | mm Hg/[ml/min] |
| Renal Vascular Resistance (mm Hg/[ml/Min]) | Acetazolamide | after acetazolamide/furosemide administration | 0.088 | Standard Deviation 0.021 | mm Hg/[ml/min] |
| Renal Vascular Resistance (mm Hg/[ml/Min]) | Furosemide | after acetazolamide/furosemide administration | 0.080 | Standard Deviation 0.019 | mm Hg/[ml/min] |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| First Intervention(1 Day) | STARTED | Acetazolamide First, Then Furosemide | 7 | |
| First Intervention(1 Day) | STARTED | Furosemide First , Than Acetazolamide | 6 | |
| First Intervention(1 Day) | COMPLETED | Acetazolamide First, Then Furosemide | 7 | |
| First Intervention(1 Day) | COMPLETED | Furosemide First , Than Acetazolamide | 5 | |
| First Intervention(1 Day) | NOT COMPLETED | Acetazolamide First, Then Furosemide | 0 | |
| First Intervention(1 Day) | NOT COMPLETED | Furosemide First , Than Acetazolamide | 1 | |
| Second Intervention (1 Day) | STARTED | Acetazolamide First, Then Furosemide | 7 | |
| Second Intervention (1 Day) | STARTED | Furosemide First , Than Acetazolamide | 5 | |
| Second Intervention (1 Day) | COMPLETED | Acetazolamide First, Then Furosemide | 7 | |
| Second Intervention (1 Day) | COMPLETED | Furosemide First , Than Acetazolamide | 5 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events12
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | hand paresthesia | General disorders | Acetazolamide | 2 | 12 | 2 |
| other | hand paresthesia | General disorders | Furosemide | 0 | 12 | 0 |
| other | hand paresthesia | General disorders | P-aminohippuric Acid | 0 | 12 | 0 |
| other | lip parestesia | General disorders | Acetazolamide | 1 | 12 | 1 |
| other | lip parestesia | General disorders | Furosemide | 0 | 12 | 0 |
| other | lip parestesia | General disorders | P-aminohippuric Acid | 0 | 12 | 0 |
| other | alteration of the sense of taste | General disorders | Acetazolamide | 1 | 12 | 1 |
| other | alteration of the sense of taste | General disorders | Furosemide | 0 | 12 | 0 |
| other | alteration of the sense of taste | General disorders | P-aminohippuric Acid | 0 | 12 | 0 |
| serious | angioedema | Skin and subcutaneous tissue disorders | Acetazolamide | 0 | 0 | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Acetazolamide | ||
| Total, all-cause mortality | Furosemide | ||
| Total, all-cause mortality | P-aminohippuric Acid | ||
| Total, other adverse events | Acetazolamide | 3 | 12 |
| Total, other adverse events | Furosemide | 0 | 12 |
| Total, other adverse events | P-aminohippuric Acid | 0 | 12 |
| Total, serious adverse events | Acetazolamide | 0 | 0 |
| Total, serious adverse events | Furosemide | 0 | 0 |
| Total, serious adverse events | P-aminohippuric Acid | 1 | 13 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01146288
GET https://conductscience.org/api/trials/v1/NCT01146288/registered